VERA vs. ASND, LEGN, CERE, VKTX, ITCI, JAZZ, BPMC, BBIO, IONS, and OGN
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Ionis Pharmaceuticals (IONS), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical preparations" industry.
Vera Therapeutics (NASDAQ:VERA) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
Vera Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -152.68%. Vera Therapeutics' return on equity of -52.43% beat Ascendis Pharma A/S's return on equity.
In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for Vera Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.91 beat Vera Therapeutics' score of 0.70 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.
Ascendis Pharma A/S received 386 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 65.45% of users gave Ascendis Pharma A/S an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.
Vera Therapeutics presently has a consensus target price of $42.86, indicating a potential upside of 12.81%. Ascendis Pharma A/S has a consensus target price of $179.44, indicating a potential upside of 32.82%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Vera Therapeutics.
Vera Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Vera Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Vera Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
99.2% of Vera Therapeutics shares are held by institutional investors. 21.7% of Vera Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Vera Therapeutics and Ascendis Pharma A/S tied by winning 9 of the 18 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
